The founder of cannabinoid science authored the definitive review of how your body's own cannabis-like molecules regulate anxiety, mood, memory, appetite, and nearly every other brain function.
Anyone who wants to understand why cannabis affects the mind the way it does — told by the scientist who discovered the system that makes it possible.
7 brain domainsregulated by the endocannabinoid system: anxiety, depression, neurogenesis, reward, cognition, learning, and memory
The Backstory
Your body is running on cannabis right now.
Not the plant. Your brain is producing its own cannabis-like molecules — endocannabinoids — every second of every day. They regulate your mood as you read this sentence. They modulate the pain signals from wherever you're sitting. They're involved in whether you feel hungry, anxious, sleepy, or focused. They shaped the memories you formed yesterday and the ones you're forming now.
This is the endocannabinoid system. It exists in every vertebrate animal. It has been conserved for over 500 million years of evolution. And until Raphael Mechoulam's work, nobody knew it existed.
In 2013 — nearly fifty years after isolating THC and two decades after discovering anandamide — Mechoulam published his masterwork: a comprehensive review of what the endocannabinoid system does in the brain, written for the Annual Review of Psychology. It remains the single best entry point for understanding why cannabis affects the mind the way it does.
Why Psychology?
The choice of journal was deliberate and revealing. Mechoulam was a chemist. He could have published this review in a pharmacology journal, a neuroscience journal, or a general science journal. Instead, he chose the Annual Review of Psychology — one of the most prestigious and selective review series in the behavioral sciences, where authors are invited, not applicants.
The message was clear: the endocannabinoid system isn't a pharmacological curiosity. It's a fundamental brain system, as important to understanding human psychology as the dopamine, serotonin, or GABA systems. It governs the functions that most directly shape subjective experience — anxiety, mood, memory, reward, and the capacity to learn.
Mechoulam co-authored the review with Linda Parker, a neuroscientist at the University of Guelph in Ontario who had spent years studying how the ECS regulates nausea, vomiting, and conditioned responses. Together, they covered seven major domains of brain function.
The Seven Domains
Process
What the Endocannabinoid System Regulates in the Brain
Anxiety
Depression
Neurogenesis
Reward
Cognition
Learning
Memory
Mechoulam & Parker (2013), Annu Rev Psychol 64:21-47
The breadth is staggering. This isn't a system that does one thing. It's a regulatory layer that sits on top of virtually every major brain function, fine-tuning the balance between too much and too little activity. When the ECS works properly, you don't notice it — anxiety stays manageable, memories form and fade appropriately, reward feels proportionate to effort. When it's disrupted, everything shifts.
The Biphasic Paradox
The most important insight in the review — the one that explains more about cannabis than almost any other finding — is that the endocannabinoid system is consistently biphasic.
Low Cannabinoid Activity
- Reduces anxiety (anxiolytic)
- Enhances mood and reward sensitivity
- Facilitates extinction of fearful memories
- Promotes neurogenesis in the hippocampus
- Supports flexible, adaptive behavior
Therapeutic window — where cannabis 'works' for anxiety and mood
High Cannabinoid Activity
- Increases anxiety and paranoia (anxiogenic)
- Impairs short-term memory formation
- Disrupts motivation and reward processing
- Can trigger psychotic symptoms in vulnerable individuals
- Produces cognitive rigidity and amotivation
Harmful range — where chronic heavy use causes problems
Mechoulam & Parker (2013), Annu Rev Psychol 64:21-47
This single concept explains a remarkable number of cannabis phenomena:
Why cannabis "stopped working" for your anxiety. At first, a small amount of THC supplemented your endocannabinoid signaling, reducing anxiety. As tolerance developed and doses escalated, you crossed from the therapeutic zone into the harmful one. The same drug, the same receptors, the opposite effect.
Why some people get paranoid and others don't. Individual differences in baseline endocannabinoid tone, CB1 receptor density, and FAAH enzyme activity mean that the same dose of THC pushes different people to different points on the biphasic curve.
Why withdrawal hits so many systems at once. Chronic THC use downregulates CB1 receptors across the brain. When you stop, endocannabinoid signaling drops below the normal baseline in all seven domains simultaneously. Anxiety spikes. Sleep collapses. Appetite disappears. Mood destabilizes. Memory feels foggy. It's not seven separate problems — it's one system failing across seven functions.
How It Actually Works
Biological Mechanism
Endocannabinoid Retrograde Signaling
Postsynaptic activation
A neuron receives a signal and becomes active. If the signal is too strong or too prolonged, the neuron needs a way to say 'quiet down.'
On-demand synthesis
The active neuron synthesizes endocannabinoids (anandamide or 2-AG) from membrane lipids. Unlike stored neurotransmitters, they're made fresh, on the spot, only when needed.
Retrograde travel
The endocannabinoids cross back across the synapse — traveling backwards to the presynaptic neuron that sent the original signal.
CB1 binding
They bind to CB1 receptors on the sending neuron, which reduces its neurotransmitter release. The message: 'You're sending too much. Dial it back.'
Rapid degradation
FAAH breaks down anandamide, MAGL breaks down 2-AG. The signal is short-lived and local. Precision, not flooding.
Mechoulam & Parker (2013); Piomelli (2003)
This is why the comparison between endocannabinoids and THC matters so much. Your body's own system is precise — endocannabinoids are made on demand, act locally, and are degraded within seconds. THC from cannabis does the opposite: it floods every CB1 receptor in the brain simultaneously, for hours, regardless of whether any particular circuit needs modulation.
Myth vs. Reality
THC does the same thing as your body's own endocannabinoids, just from outside.
THC activates the same receptors, but the signaling pattern is fundamentally different. Endocannabinoids are synthesized on demand at specific synapses, act for seconds, and are rapidly degraded. THC arrives everywhere at once, activates receptors that don't need activating, and persists for hours. It's like the difference between a thermostat adjusting your home temperature by one degree and someone setting every radiator in the building to maximum.
The Evidence
Endocannabinoid signaling is retrograde, on-demand, local, and transient. THC is exogenous, global, non-selective, and persistent. This difference — not the receptor binding itself — explains why chronic THC use causes problems that endocannabinoid signaling doesn't.
Mechoulam & Parker (2013); Piomelli (2003), Nat Rev Neurosci
Extinction Learning: The Therapeutic Frontier
One of the most clinically significant sections of the review concerned extinction learning — the brain's process for unlearning fear responses. When you have a traumatic experience and later learn that the trigger is no longer dangerous, that's extinction. It doesn't erase the original memory; it creates a new, competing memory that suppresses the fear response.
The ECS is critical to this process. Endocannabinoid signaling in the amygdala and prefrontal cortex facilitates extinction — helping the brain update its threat assessments. This has direct implications for PTSD, where extinction is impaired and traumatic memories remain perpetually active.
The Authors
By 2013, Mechoulam was 82 years old — and being invited to write for the Annual Review of Psychology represented something remarkable. A chemist who had spent his career in a pharmacology lab was now being asked to define how psychologists should understand the brain. His co-author, Linda Parker, brought complementary expertise. Where Mechoulam's work had been primarily molecular — isolating compounds, characterizing receptors — Parker had spent years studying how the ECS shapes behavioral responses. Her lab had done foundational work on cannabinoid regulation of nausea and vomiting, taste aversion, and conditioned responses.
Together, they wrote something neither could have produced alone: a review that translated molecular pharmacology into psychological function, bridging the gap between what the ECS is and what it means for human experience.
What It Means for Cannabis Users
The biphasic model that Mechoulam and Parker described has practical implications that most cannabis users never hear about:
Tolerance breaks aren't just about reducing tolerance. They're about allowing CB1 receptors to upregulate back to normal density — restoring the precision signaling that chronic THC exposure disrupted. Research suggests CB1 receptors begin recovering within days and substantially normalize within 2-4 weeks.
Microdosing has a pharmacological rationale. The biphasic curve means there's a dose window where cannabinoid supplementation could genuinely reduce anxiety without causing the problems associated with heavy use. The challenge is that the window is narrow and individual.
Withdrawal is temporary. The ECS is one of the oldest and most resilient biological systems in vertebrate evolution. It recovered from the asteroid that killed the dinosaurs. It will recover from your tolerance break.
Related Research
Building the Map of the Brain's Cannabis System
This review synthesized decades of discovery. These are the foundational studies it built upon.
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni & Mechoulam (1964)
Where it started — THC identified. Without the structure, you can't study how it works in the brain.
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
Devane, Hanus & Mechoulam (1992)
Anandamide — the first endocannabinoid. Proof that the brain makes its own cannabis-like molecules.
The molecular logic of endocannabinoid signalling
Piomelli (2003)
The mechanistic blueprint for how endocannabinoid signaling works at the synapse.
The endocannabinoid system as an emerging target of pharmacotherapy
Pacher, Bátkai & Kunos (2006)
The therapeutic map — every disease where the ECS plays a role. This review narrowed the focus to the brain.
Discovery of 2-AG
Stella, Schweitzer & Piomelli (1997)
The second endocannabinoid — 170x more abundant than anandamide, and the primary retrograde messenger at synapses.
What is the endocannabinoid system in simple terms?
It's a biological system in your body that uses cannabis-like molecules (endocannabinoids) to regulate mood, anxiety, pain, appetite, memory, and immune function. It works by having neurons produce these molecules on demand to fine-tune brain activity — turning signals up or down as needed. THC from cannabis works because it happens to fit into this system's receptors.
What does 'biphasic' mean for cannabis use?
It means the same compound produces opposite effects at different doses. A small amount of THC tends to reduce anxiety, enhance mood, and facilitate learning. A larger amount tends to increase anxiety, impair memory, and disrupt motivation. This is why cannabis can feel therapeutic at first and problematic later as tolerance drives doses higher.
Why does cannabis withdrawal affect so many different functions?
Because the endocannabinoid system simultaneously regulates anxiety, sleep, appetite, mood, pain, and memory. Chronic cannabis use causes CB1 receptors to downregulate across the brain. When you stop, endocannabinoid signaling drops below baseline in all of these domains at once — producing the characteristic cluster of withdrawal symptoms.
Does the endocannabinoid system recover after quitting cannabis?
Yes. Research shows that CB1 receptors begin upregulating within days of cessation and substantially normalize within 2-4 weeks. The system is one of the oldest and most resilient in vertebrate biology — it has been maintained by evolution for over 500 million years.
What the researchers found
Mechoulam and Parker systematically reviewed how the endocannabinoid system regulates brain function across seven major domains: anxiety, depression, neurogenesis, reward, cognition, learning, and memory. A critical finding was that endocannabinoid effects are consistently biphasic — low doses of cannabinoids reduce anxiety, enhance reward, and facilitate certain forms of memory, while high doses produce the opposite effects. The review established that the ECS is not a simple on/off system but a precision regulatory network where dose, timing, and context determine whether the outcome is therapeutic or harmful.
Why it matters
This was the founder of the field writing for an audience of psychologists — translating five decades of cannabinoid pharmacology into its implications for understanding the human mind. Published in the Annual Review of Psychology, it represented the definitive statement that the ECS is fundamentally a brain system, governing the psychological functions that most directly shape human experience.
The numbers in context
CB1 receptors: most abundant GPCR in the human brain
Anandamide: first endocannabinoid, partial CB1 agonist
2-AG: second endocannabinoid, 170x more abundant than anandamide, full CB1 agonist
Biphasic dose response: low-dose anxiolytic → high-dose anxiogenic
26 pages covering 7 brain function domains
How the study worked
Comprehensive narrative review published in the Annual Review of Psychology. Synthesizes preclinical and clinical evidence across multiple domains of brain function, authored by the discoverer of THC and anandamide.
What this study cannot tell us
A narrative review, not a systematic review or meta-analysis. Reflects the authors' expert synthesis rather than a standardized evidence assessment. Published in 2013 — significant developments in clinical cannabinoid research (especially the Epidiolex trials and cannabis-psychosis epidemiology) occurred after publication.
How to read the evidence
An authoritative narrative review in a top-tier psychology journal, written by the most important figure in cannabinoid science. Not a systematic review, but carries unmatched authority as a synthesis.
When this study was published
Published in 2013. The biphasic dose-response framework and ECS fundamentals remain current. Clinical evidence (especially for CBD therapeutics) has expanded significantly since publication.
The bigger picture
This review cemented the ECS as a mainstream topic in psychology and neuroscience — no longer a pharmacological curiosity but a fundamental brain system comparable in importance to the dopamine, serotonin, or GABA systems. It provided the mechanistic framework for understanding why cannabis withdrawal disrupts so many psychological functions simultaneously and why dose matters more than most users realize.
Questions still open
- Can the ECS biphasic response be exploited therapeutically — using low-dose cannabinoids for anxiety while avoiding high-dose harms?
- How does chronic cannabis use alter endocannabinoid tone, and is the alteration reversible?
- Could endocannabinoid-enhancing drugs (like FAAH inhibitors) provide therapeutic benefits without the risks of direct CB1 agonists?
- Why do some individuals show primarily anxiolytic responses to cannabis while others show anxiogenic responses?
Common questions
What is the endocannabinoid system?
What does 'biphasic' mean for cannabis?
Why does cannabis withdrawal affect so many different things?
Is the endocannabinoid system only about cannabis?
Read the original research
The endocannabinoid system and the brain.
Annual review of psychology, 64, 21-47
One of the most prestigious review journals in psychology. Annual Reviews publishes authoritative, comprehensive reviews by leading researchers.
Citation
Mechoulam, Raphael; Parker, Linda A. (2013). The endocannabinoid system and the brain.. Annual review of psychology, 64, 21-47. https://doi.org/10.1146/annurev-psych-113011-143739
Explore the wider topic
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- How Long for Cannabinoid Receptors to Return to Normal
- Weed and Motivation: Is Amotivational Syndrome Real?
- Dopamine Recovery After Quitting Weed: What the Science Says
- How Weed Rewires Your Reward System (And How to Reset It)